CRC

Encorafenib Receives FDA Approval for BRAF-Positive Colorectal Cancer

BRAF mutations occur in approximately 15% of patients with metastatic colorectal cancer (mCRC) and are associated with a poor prognosis and limited treatment options. On April 8, 2020, the US FDA announced approval of the BRAF inhibitor encorafenib in combination with the EGFR inhibitor cetuximab as treatment for patients with BRAF V600E-mutated mCRC who have […]

Read More

Link Between COPD and Lung Cancer in Never Smokers

According to a study published last month in Thorax, individuals with chronic obstructive pulmonary disease (COPD) with no history of smoking have higher risk of developing lung cancer than smokers without COPD. This information comes from an observational cohort study evaluated data from 338,548 individuals aged 40 to 84 years from the National Health Insurance […]

Read More

New Cell-Free DNA-Based Multitumor Diagnostic Test

In recent years, next-generation sequencing (NGS) of cell-free tumor DNA (cfDNA) has become a common part method of testing for genetic mutations in patients with cancer. Currently, most of these tests are tumor-specific and used after diagnosis to guide treatment selection. However, a new cfDNA test that is currently in development is designed to detect […]

Read More

Covid19

Guidance on Cancer Surgery During COVID-19 Outbreak

As rates of COVID-19 continue to rise, resources in hospitals around the country are dwindling. In response to this, many hospitals have canceled elective surgery, as recommended by the American College of Surgeon (ACS). Furthermore, new guidance for surgeons released on March 24, 2020, suggests that many cancer-specific surgeries will need to be delayed. Although […]

Read More

Improved PFS With SABR for Oligometastatic Prostate Cancer

The optimal treatment approach for men with hormone-sensitive prostate cancer (HSPC) who develop oligometastatic disease is not well defined. While many of these patients receive androgen deprivation therapy (ADT) or observation, some studies have suggested that localized treatment with radiotherapy may be a beneficial alternative. In the phase II ORIOLE trial, stereotactic ablative radiotherapy (SABR) […]

Read More

Anthracycline

Right Ventricle Cardiotoxicity From Anthracycline Chemotherapy

Anthracycline chemotherapy is a common component of many cancer treatment regimens. These chemotherapies are highly effective, but are sometimes associated with increased rates of cardiac toxicity. During chemotherapy treatment, cardiotoxicity is monitored by measuring changes in the left ventricle ejection fraction (LVEF). However, according to a recent study, the right ventricle (RV) may be more heavily […]

Read More

COVID19

COVID-19 a Threat to Oncology Patients

Currently, the novel coronavirus SARS-CoV-2, which causes the disease known as COVID-19, is infecting patients globally at a rapid rate. While understanding of this virus continues to evolve, older individuals and those with preexisting conditions are particularly vulnerable. Because of their immunocompromised status, patients with cancer may present a particularly high-risk population. According to a […]

Read More